Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances.
There remains debate regarding the impact of cannabis on neuropsychiatric disorders. Here, we examined the effects of cannabidiol (CBD), a nonpsychoactive constituent of cannabis, on heroin self-administration and drug-seeking behavior using an experimental rat model. CBD (5-20 mg/kg) did not alter stable intake of heroin self-administration, extinction behavior, or drug seeking induced by a heroin prime injection. Instead, it specifically attenuated heroin-seeking behavior reinstated by exposure to a conditioned stimulus cue. CBD had a protracted effect with significance evident after 24 h and even 2 weeks after administration. The behavioral effects were paralleled by neurobiological alterations in the glutamatergic and endocannabinoid systems. Discrete disturbances of AMPA GluR1 and cannabinoid type-1 receptor expression observed in the nucleus accumbens associated with stimulus cue-induced heroin seeking were normalized by CBD treatment. The findings highlight the unique contributions of distinct cannabis constituents to addiction vulnerability and suggest that CBD may be a potential treatment for heroin craving and relapse.
Pubmed ID: 19940171 RIS Download
Animals | Cannabidiol | Cannabinoid Receptor Modulators | Conditioning (Psychology) | Cues | Disease Models, Animal | Glutamic Acid | Heroin | Heroin Dependence | Limbic System | Male | Narcotic Antagonists | Narcotics | Neural Pathways | Nucleus Accumbens | Rats | Rats, Long-Evans | Receptor, Cannabinoid, CB1 | Receptors, AMPA | Treatment Outcome | Ventral Tegmental Area